Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug optionsByBruce GilPublishedApril 2, 2025
Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slumpByBruce GilPublishedApril 2, 2025
Here's how much Ozempic and similar drugs have soared in popularity since 2018ByBruce GilPublishedApril 1, 2025
Moderna and other vaccine stocks fall after a top FDA official quitsByBruce GilPublishedMarch 31, 2025
Eli Lilly's Alzheimer's drug is rejected by EU regulators over brain swelling risk, despite U.S. approvalByBruce GilPublishedMarch 28, 2025
Cheaper Wegovy, 23andMe shutters, and RFK Jr. cuts FDA jobs: Pharma news roundupByBruce GilPublishedMarch 28, 2025
Wegovy sales took a hit this year. Novo's CEO blames off-brand competitionByBruce GilPublishedMarch 27, 2025
RFK Jr. plans to cut 3,500 jobs at the FDA, as staff is reportedly already struggling with workloadByBruce GilPublishedMarch 27, 2025
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’sByBruce GilPublishedMarch 27, 2025
GLP-1s are driving returns on R&D investments for Big Pharma, report saysByBruce GilPublishedMarch 25, 2025
Novo Nordisk's weight loss drug Wegovy is now cheaper for even more patientsByBruce GilPublishedMarch 24, 2025
Anne Wojcicki resigns as 23AndMe files for Chapter 11 bankruptcyByWilliam GavinPublishedMarch 24, 2025
8 key drug patents expiring soon — and what it means for the marketByBruce GilPublishedMarch 24, 2025
Johnson & Johnson is the latest pharma giant to court Trump with new investment plansByBruce GilPublishedMarch 21, 2025
The cost of GLP-1s needs to come way down for benefits to be worth it, study saysByBruce GilPublishedMarch 17, 2025
The weight loss drug shortage is over — and some patients are 'panicking'ByBruce GilPublishedMarch 17, 2025
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundupByBruce GilPublishedMarch 14, 2025
